




H1 and Q2 2024 Results

Conference call and webcast
for investors and analysts

25 July 2024



Forward-looking statements

In order, among other things, to utilise the 'safe harbour' provisions of the US Private Securities Litigation Reform Act of 1995, AstraZeneca (hereafter 'the Group') provides the following cautionary statement: This document contains certain forward-looking statements with respect to the operations, performance and financial condition of the Group, including, among other things, statements about expected revenues, margins, earnings per share or other financial or other measures. Although the Group believes its expectations are based on reasonable assumptions, any forward-looking statements, by their very nature, involve risks and uncertainties and may be influenced by factors that could cause actual outcomes and results to be materially different from those predicted. The forward-looking statements reflect knowledge and information available at the date of preparation of this document and the Group undertakes no obligation to update these forward-looking statements. The Group identifies the forward-looking statements by using the words 'anticipates', 'believes', 'expects', 'intends' and similar expressions in such statements. Important factors that could cause actual results to differ materially from those contained in forward-looking statements, certain of which are beyond the Group's control, include, among other things: the risk of failure or delay in delivery of pipeline or launch of new medicines; the risk of failure to meet regulatory or ethical requirements for medicine development or approval; the risk of failures or delays in the quality or execution of the Group's commercial strategies; the risk of pricing, affordability, access and competitive pressures; the risk of failure to maintain supply of compliant, quality medicines; the risk of illegal trade in the Group's medicines; the impact of reliance on third-party goods and services; the risk of failure in information technology or cybersecurity; the risk of failure of critical processes; the risk of failure to collect and manage data in line with legal and regulatory requirements and strategic objectives; the risk of failure to attract, develop, engage and retain a diverse, talented and capable workforce; the risk of failure to meet regulatory or ethical expectations on environmental impact, including climate change; the risk of the safety and efficacy of marketed medicines being questioned; the risk of adverse outcome of litigation and/or governmental investigations; intellectual property-related risks to the Group's products; the risk of failure to achieve strategic plans or meet targets or expectations; the risk of failure in financial control or the occurrence of fraud; the risk of unexpected deterioration in the Group's financial position; the impact that global and/or geopolitical events may have or continue to have on these risks, on the Group's ability to continue to mitigate these risks, and on the Group's operations, financial results or financial condition. Nothing in this document, or any related presentation/webcast, should be construed as a profit forecast.



H1 and Q2 2024 Results

Conference call agenda

CEO Opening Remarks

Pascal Soriot

Chief Executive Officer

Financial Results

Aradhana Sarin

Chief Financial Officer

Oncology

Dave Fredrickson

EVP, Oncology Business

Susan Galbraith

EVP, Oncology R&D

BioPharmaceuticals

Ruud Dobber

EVP, BioPharmaceuticals Business

Sharon Barr

EVP, BioPharmaceuticals R&D

Rare Disease


Marc Dunoyer

Chief Executive Officer, Alexion

CEO Closing Remarks, Q&A

Pascal Soriot


Chief Executive Officer



CEO Opening Remarks

Pascal Soriot


CHIEF EXECUTIVE OFFICER



H1 2024 – strong underlying growth, Total Revenue +18%

Total Revenue | 18% CER

\$m



Core Operating Profit | 7% CER



Core EPS | 5% CER




Upgraded FY 2024 guidance – Total Revenue and Core EPS expected to increase by mid teens percentage



H1 2024 – very strong performance across diverse, broad-based business


Continued growth across key geographies

H1 2024 Total Revenue, \$m



Double-digit growth across key therapy areas

H1 2024 Total Revenue¹, \$m



1. Other Medicines delivered \$573m in Total Revenue in H1 2024.

6 All growth rates at CER. Due to rounding, the sum of a number or dollar values and percentages may not agree to totals.

Appendix: [Glossary](#).



Significant pipeline momentum in H1 2024



Key positive Phase III readouts

ADRIATIC

Imfinzi potential first IO therapy in LS-SCLC

LAURA

Tagrisso expanding in early-stage *EGFRm* NSCLC

DESTINY-Breast06

Enhertu moving into CTx naïve mBC, benefit in HER2-ultralow

ECHO

Calquence first BTKi to show favourable OS trend in 1L MCL

NIAGARA

Imfinzi potential first IO regimen to extend survival in MIBC



Transformative new approvals and launches First region approved

Tagrisso + CTx

FLAURA2 reinforces *Tagrisso* as TKI backbone in 1L NSCLC

Enhertu

Tumour agnostic approval expands *Enhertu* in solid tumours

Ultomiris

Expanding *Ultomiris* in neurology with NMOSD approval

Airsupra

Airsupra is first ICS/SABA combination treatment for asthma


Imfinzi

Imfinzi approval for endometrial patients with mismatch repair deficient disease, based on DUO-E




Financial Results

Aradhana Sarin
CHIEF FINANCIAL OFFICER



H1 and Q2 2024 – Reported profit and loss



	H1 2024 \$m	CER change %	% Total Revenue	Q2 2024 \$m	CER change %	% Total Revenue
Total Revenue	25,617	18	100	12,938	17	100
- Product Sales	24,629	18	96	12,452	18	96
- Alliance Revenue	939	50	4	482	42	4
- Collaboration Revenue	49	(78)	-	4	(98)	-
Product Sales Gross Margin ¹	82.1%	-		82.5%	-	
Total operating expense ²	(15,482)	7	60	(8,069)	5	62
- R&D expense	(5,791)	10	23	(3,008)	13	23
- SG&A expense	(9,424)	6	37	(4,929)	1	38
Other operating income and expense	127	(89)	-	60	(92)	-
Operating profit	5,861	25	23	2,746	20	21
Tax rate	21%			20%		
Reported EPS	\$2.65	23		\$1.24	15	


Due to rounding, the sum of a number of dollar values and percentages may not agree to totals. Absolute values at actual exchange rates; changes at CER.

1. Product Sales Gross Margin excludes the impact of Alliance and Collaboration Revenue and any associated costs, thereby reflecting the underlying performance of Product Sales. 2. Total operating expense includes distribution, R&D and SG&A expenses.

Appendix: [Glossary](#).



H1 and Q2 2024 – Core profit and loss



	H1 2024 \$m	CER change %	% Total Revenue	Q2 2024 \$m	CER change %	% Total Revenue
Total Revenue	25,617	18	100	12,938	17	100
- Product Sales	24,629	18	96	12,452	18	96
- Alliance Revenue	939	50	4	482	42	4
- Collaboration Revenue	49	(78)	-	4	(98)	-
Product Sales Gross Margin ¹	82.4%	-1pp		82.7%	-	
Total operating expense ²	(12,985)	15	51	(6,739)	14	52
- R&D expense	(5,570)	15	22	(2,872)	13	22
- SG&A expense	(7,148)	15	28	(3,735)	16	29
Other operating income and expense	125	(89)	-	60	(92)	-
Operating profit	8,411	7	33	4,101	1	32
Tax rate	20%			19%		
Core EPS	\$4.03	5		\$1.98	(3)	

Due to rounding, the sum of a number of dollar values and percentages may not agree to totals. Absolute values at actual exchange rates; changes at CER.

1. Product Sales Gross Margin excludes the impact of Alliance and Collaboration Revenue and any associated costs, thereby reflecting the underlying performance of Product Sales. 2. Total operating expense includes distribution, R&D and SG&A expenses.


Appendix: [Glossary](#).



Net debt and capital expenditure

Net cash inflow from operating activities increased 15% in H1 2024

Net debt bridge



Capital expenditure

- Anticipate ~50% increase in tangible capex in 2024, due to investment in capacity and capabilities
- Tangible capex \$799m in H1 2024, reflects maintenance and new investments:
 - API facility in Ireland
 - Inhaled manufacturing site in Qingdao, CN
 - Cell therapy manufacturing site in Rockville, MD
- Planned end-to-end ADC manufacturing site in Singapore announced in May 2024

Net debt/Adjusted EBITDA 1.8x

Due to rounding, the sum of a number of dollar values and percentages may not agree to totals. 1. Comprises disposal of intangible assets, movement in profit participation liability, purchase of intangible assets, payment of contingent consideration on business combinations, purchase and disposal of non-current asset investments, payment of Acerta Pharma share purchase liability and acquisitions of subsidiaries, net of cash acquired. The Company uses Debt issuance to finance new Business Development opportunities

11 2. Rolling 12m EBITDA adding back the impact of unwind of inventory fair value uplift recognised on acquisition of Alexion of \$59m (FY 2023: \$114m). AstraZeneca credit ratings: Moody's: short-term rating P-1, long-term rating A2, outlook stable. S&P Global Ratings: short-term rating A-1, long-term rating A, outlook stable. 3. If foreign exchange rates for July to December were to remain at the average rates seen in June 2024. Appendix: [Glossary](#).

Global demand growth across leading medicines

Top medicines by H1 2024 Total Revenue

	Total Revenue \$ million		Growth vs. PY CER%
<i>Farxiga</i>	3,836		38%
<i>Tagrisso</i>	3,203		13%
<i>Imfinzi</i>	2,259		25%
<i>Ultomiris</i>	1,804		35%
<i>Calquence</i>	1,508		28%
<i>Symbicort</i>	1,491		19%
<i>Lynparza</i>	1,450		9%
<i>Soliris</i>	1,439		-8%
<i>Enhertu</i>	932		62%
<i>Fasenra</i>	781		6%
<i>Strensiq</i>	653		18%

Strong underlying growth supports upgraded FY 2024 guidance

FY 2024 guidance

Upgraded FY 2024 guidance at CER reflecting strong underlying performance

Total Revenue

- **Mid teens percentage increase**
(previously low double-digit to low teens)

Core EPS

- **Mid teens percentage increase**
(previously low double-digit to low teens)

Other guidance indications

- An increase in Collaboration Revenue is not assumed in the upgraded guidance *(previously assumed a substantial increase)*
- Other operating income is expected to decrease substantially (FY 2023 included a \$241m gain on the disposal of *Pulmicort Flexhaler* US rights, and a \$712m one-time gain relating to updates to contractual arrangements for *Beyfortus*)
- Core Tax Rate is expected to be between 18-22%


Anticipated FX impact – low single-digit adverse impact on Total Revenue and mid single-digit adverse impact on Core EPS¹

Oncology



Dave Fredrickson
ONCOLOGY BUSINESS

Susan Galbraith
ONCOLOGY R&D




Oncology – H1 and Q2 2024

Total Revenue +22% in H1 2024 driven by global demand for key medicines

Oncology

H1 2024 \$10.4bn, +22%



Q2 2024: key dynamics

- **Tagrisso** +12%, ADAURA, FLAURA and FLAURA2 strong global demand
- **Calquence** +22%, sustained BTKi leadership in 1L CLL
- **Imfinzi** +18%, demand growth, offset by JP repricing effective February 2024
- **Imjudo** +19%, continued HCC (HIMALAYA) and NSCLC (POSEIDON) growth
- **Lynparza PS** +7%, continued PARPi leadership
- **Enhertu** +49%, continued demand in HER2+ (DB03) and HER2-low (DB04), encouraging early launch in tumour agnostic
- **Truqap** n/m, strong adoption in biomarker-altered population

-
- New indications: US (*Imfinzi* DUO-E), EU (*Truqap* CAPI-291, *Tagrisso* FLAURA2), JP (*Tagrisso* FLAURA2), CN (*Tagrisso* FLAURA2)



Oncology – R&D highlights

Positive readouts expand AstraZeneca presence across key tumour types

Practice changing data at ASCO and EHA

LAURA

Tagrisso first targeted therapy to show benefit in *EGFR* Stg. III u/r NSCLC¹



ADRIATIC

Imfinzi first IO to demonstrate overall survival benefit in limited-stage SCLC²

US breakthrough designation



DESTINY-Breast06


Enhertu redefining HER2 expression, moving earlier into chemo-naïve setting³

ECHO

Calquence first BTKi to show favourable trend on survival in untreated MCL⁴

Expanding oncology leadership into bladder cancer

NIAGARA – first IO regimen before and after surgery to extend survival in muscle-invasive bladder cancer



Robust bladder development programme with *Imfinzi*

POTOMAC | H1 2025

VOLGA | H2 2025

NILE | H2 2024

NMIBC



MIBC



metastatic

¹First denotes firsts in Phase III global trials. 1. Ramalingam SS et al. Abstract LBA4 presented at American Society of Clinical Oncology 2024; 2. Spigel DR et al. Abstract LBA5 presented at American Society of Clinical Oncology 2024; 3. Curigliano G et al. Abstract LBA1000 presented at American Society of Clinical Oncology 2024; 4. Wang M et al. Abstract LB3439 presented at European Hematology Association 2024.

Collaboration partner: Daiichi Sankyo (*Enhertu*).

Appendix: [Glossary](#).



BioPharmaceuticals




Ruud Dobber

BIOPHARMACEUTICALS BUSINESS

Sharon Barr

BIOPHARMACEUTICALS R&D




BioPharmaceuticals – H1 and Q2 2024

Total Revenue \$10.4bn, +17% – demand growth, accelerating new launch momentum

CVRM


H1 2024 \$6.2bn, +22%



Farxiga Brilinta Lokelma Other

R&I

H1 2024 \$3.8bn, +22%



Fasenra Breztri Tezspire Saphnelo Symbicort Other

Q2 2024: key dynamics

- **Farxiga** +32%, strong global demand growth
- **Wainua** n/m, accelerating new patient starts
- **Breztri** +47%, increased share in growing class
- **Tezspire** >2x, continued growth in US, increasing new patient share EU, JP and EM
- **Airsupra** n/m, encouraging launch uptake
- **Symbicort** 25%, underlying demand growth in EM and US




BioPharmaceuticals – R&D highlights

Positive readouts build confidence in CVRM pipeline multi-blockbuster potential

\$5bn+*

AZD0780 (oPCSK9) | Phase I¹ dyslipidaemia




Potential best-in-class profile – oral once-daily dosing and no interaction with food

Phase IIb data anticipated H1 2025

\$3-5bn*

balcinrenone/dapagliflozin FDC | Phase IIb MIRACLE² HF with CKD



- Only ~25% heart failure with CKD patients receive SoC MRAs due to hyperkalaemia risk
- balci/dapa FDC reduced UACR without increasing hyperkalaemia

Balanced-HF Phase III readout anticipated >2025

*Peak Year Revenue, non-risk adjusted as disclosed on Investor Day 21 May 2024.

19 1. Vega RB, et al. presented at European Atherosclerosis Society Congress; May 26-29; Lyon, France 2024; 2. Lam CSP et al. Eur J Heart Failure 2024 (in press).


Appendix: [Glossary](#).



Rare Disease

Marc Dunoyer

CHIEF EXECUTIVE OFFICER,
ALEXION




Rare Disease – H1 and Q2 2024

Total Revenue +15% in H1 2024 driven by neurology

Rare Disease

H1 2024 \$4.2bn, +15%



Ultomiris Soliris Strensiq Others¹

Q2 2024: key dynamics

C5 Franchise: sustainable, durable growth

- **Ultomiris** +36%, driven by demand growth in neurology indications (gMG, NMOSD)
- **Soliris** (8%), continued rapid conversion to *Ultomiris*, partly offset by growth in Emerging Markets

Beyond Complement: market expansion and increased demand

- **Strensiq** +14% and **Koselugo** +45%, driven by continued global demand

All growth rates at CER.

1. Includes *Kanuma* and *Koselugo*.


21 Collaboration partners: Merck & Co., Inc. (*Koselugo*).

Appendix: [Glossary](#).



Rare Disease – R&D highlights

Amolyt Pharma acquisition completed, eneboparatide Phase III anticipated H1 2025



eneboparatide | hypoparathyroidism

A rare endocrine disorder characterised by deficient or absent parathyroid hormone

 \$1-3bn*

Epidemiology

US
106K

80% 
of hypoparathyroidism patients are women

EU5
105K

>50% 
are peri- or post-menopausal women

JP
42K

75%  post-neck surgery
25% genetic, autoimmune, idiopathic

Eneboparatide binds to PTH 1 receptor

- Normalising serum calcium levels
- Decreasing urinary calcium excretion
- Preserving bone mineral density

Phase III CALYPSO
data anticipated in H1 2025

US Breakthrough Designation | US Orphan Drug Designation


Amolyt acquisition expands Alexion's presence in rare endocrinology



CEO Closing Remarks

Pascal Soriot

CHIEF EXECUTIVE OFFICER



Delivering leading growth and long-term value creation



Ambition to deliver **\$80bn in Total Revenue by 2030¹**



On track to deliver **mid-30s% Core operating margin by 2026**

Beyond 2026, Core operating margin will be influenced by portfolio evolution and the Company will target at least mid-30s%



Ambition to deliver at least **20 NMEs by 2030**



Multiple high-value medicines to drive leading growth

Existing medicines and NME opportunities with \$5bn+ potential

 *Wainua*  *Tagrisso*
 *Farxiga*  *Enhertu*
 *Imfinzi/ Imjudo*  *Ultomiris*

Existing portfolio

 camizestrant  saruparib  dapa FDCs
 Dato-DXd  AZD0486  baxdrostat
 rilvegostomig  AZD0120  AZD0780
 volrustomig  AZN ADCs  weight management

NME opportunities

AstraZeneca on track to deliver **25+ blockbusters by 2030**



AstraZeneca – rich catalyst path and confidence building news-flow supports long-term growth ambition

H2 2024 Phase III readouts and data presentations



Dato-DXd – **TB02** – TNBC



Imfinzi – **NILE** – 1L metastatic bladder



Truqap – **CAPitello-281** – dPTEN HSPC



Tezspire – **WAYPOINT** – CRwNP



Koselugo – **KOMET** – NF1-PN (adults)

Key Phase III readouts anticipated in 2025



camizestrant – **SERENA-6** – HR+/HER2- mBC



Dato-DXd – **AVANZAR** – 1L NSCLC



Enhertu – **DB11** – early HER2+ mBC



Enhertu – **DB09** – 1L HER2+ mBC



Imfinzi – **MATTERHORN** – GC/GEJC



Imfinzi – **POTOMAC** – NMIBC



Imfinzi – **VOLGA** – cis-ineligible MIBC



baxdrostat – **BaxHTN** – uncontrolled HTN



Fasenra – **RESOLUTE** – COPD



anselamimab – **AL amyloidosis**



eneboparatide – **CALYPSO** – hypopara.

2024 data build confidence in high-value, disruptive categories – IO bispecifics, ADCs, weight management



Q&A Session



Pascal Soriot
EXECUTIVE DIRECTOR &
CHIEF EXECUTIVE OFFICER



Aradhana Sarin
EXECUTIVE DIRECTOR &
CHIEF FINANCIAL OFFICER



Marc Dunoyer
CHIEF EXECUTIVE OFFICER,
ALEXION



Susan Galbraith
EXECUTIVE VICE PRESIDENT,
ONCOLOGY R&D



Dave Fredrickson
EXECUTIVE VICE PRESIDENT,
ONCOLOGY BUSINESS



Sharon Barr
EXECUTIVE VICE PRESIDENT,
BIOPHARMACEUTICALS R&D



Ruud Dobber
EXECUTIVE VICE PRESIDENT,
BIOPHARMACEUTICALS
BUSINESS



Iskra Reic
EXECUTIVE VICE PRESIDENT,
VACCINES AND IMMUNE
THERAPIES



Leon Wang
EXECUTIVE VICE PRESIDENT,
INTERNATIONAL



Appendix & Glossary

- Glossary
- Oncology tumour maps
- Emerging Markets performance
- Key medicines performance by therapy area



Glossary – abbreviations

ADC	antibody conjugate	EM	Emerging Markets	K+	Potassium	PTH	parathyroid hormone
API	active pharmaceutical ingredient	EPS	Earnings per share	LA	long-acting	QCS	quantitative continuous scoring
ASCO	American society of clinical oncology	EPS	earnings per share	LDL-C	low-density lipoprotein cholesterol	R&D	research and development
ASCO	American Society of Clinical Oncology	ERoW	Established rest of world	m	millions	R&I	Respiratory and immunology
ATTR-PN	transthyretin amyloid polyneuropathy	ET	endocrine therapy	mBC	Metastatic breast cancer	R&I	respiratory and immunology
bn	billions	EU5	France, Germany, Italy, Spain, and UK	MCL	mantle cell lymphoma	SABA	short acting beta agonist
BTD	break through designation	FDC	fixed dose combination	MIBC	muscle invasive bladder cancer	SCLC	small cell lung cancer
BTD	break through designation	FX	Foreign exchange	MRM	mineralocorticoid receptor modulator	SG&A	sales, general and administrative
BTKi	Bruton's tyrosine kinase	GC	gastric cancer	n/m	Not material	SGLT2i	sodium/glucose cotransporter 2 inhibitor
C5	complement component 5	GEJC	gastroesophageal junction cancer	NF1-PN	neurofibromatosis type 1-plexiform neurofibromas	SoC	standard of care
CER	Constant exchange rates	gem	gemcitabine	NME	new molecular entity	Stg I/II/III	Stage 1/2/3
CFO	cash flow from operating activities	Gluc	glucagon	NMIBC	non-muscle invasive bladder cancer	TIGIT	T-cell immunoreceptor with immunoglobulin and ITIM domains
cis	cisplatin	gMG	generalised myasthenia gravis	NMOSD	Neuromyelitis optica spectrum disorder	TIM-3	T-cell immunoglobulin and mucin domain-containing protein
CKD	chronic kidney disease	HCC	Hepatocellular carcinoma	NSCLC	Non-small cell lung cancer	TKI	tyrosine kinase inhibitor
CN	China	HER2+	human epidermal growth factor receptor 2 positive	ODD	orphan drug designation	TNBC	triple negative breast cancer
CRwNP	chronic rhinosinusitis with nasal polyps	HER2-low	human epidermal growth factor receptor 2 low	ODD	orphan drug designation	u/r	unresectable / resectable
CTLA-4	cytotoxic T-lymphocyte associated protein 4	HR+	hormone receptor positive	oGLP1	oral glucagon-like receptor peptide 1	UACR	urinary albumin/creatinine ratio
CTx	chemotherapy	HTN	hypertension	OOI	other operating income	V&I	Vaccines and Immune Therapies
CVRM	Cardiovascular, renal and metabolism	ICS	inhaled corticosteroid	oPCSK9	oral protein convertase subtilisin/kexin type 9		
dPTEN	phosphatase and tensin homolog deficient	IL5	Interleukin 5	OS	overall survival		
EBITDA	Earnings before interest, tax, depreciation and amortisation	IO	Immuno-oncology	PARPi	poly-ADP ribose polymerase inhibitor		
EGFRm	epidermal growth factor receptor mutant	IO	Immuno-oncology	PD1	programmed cell death protein 1		
EHA	European Hematology Association	JP	Japan	PD-L1	programmed cell death ligand 1		

AstraZeneca in Lung Cancer

Ambition for >50% of lung cancer patients to be eligible for AZN medicine by 2030

	resectable	unresectable		metastatic	
	Stg. I-III	Stg. I-II	Stg. III	1L	2L+
Est. epi (G7)	~200K	~30K	~70K	~350K	~290K
IO sensitive c.70%	<i>Imfinzi</i> AEGEAN	<i>Imfinzi</i> / <i>Osi</i> w/ SBRT PACIFIC-4	CRT → <i>Imfinzi</i> PACIFIC	<i>Imfinzi</i> + <i>Imjudo</i> + CTx POSEIDON	<i>Imfinzi</i> + ceralasertib LATIFY
	volrustomig + CTx <i>Imfinzi</i> + Dato + plat NEOCOAST-2		<i>Imfinzi</i> combos PACIFIC-8, -9 improvements across PD-L1 spectrum	Dato-DXd + IO +/- Platinum TROPION-Lung08/TROPION-Lung07/AVANZAR	Dato-DXd TROPION-Lung01
EGFRm c.16%	<i>Tagrisso</i> ADAURA	<i>Imfinzi</i> / <i>Osi</i> w/ SBRT PACIFIC-4	CRT → <i>Tagrisso</i> LAURA	<i>Tagrisso</i> FLAURA	savolitinib + <i>Tagrisso</i> SAFFRON/SAVANNAH
	<i>Tagrisso</i> neoADAURA			<i>Tagrisso</i> + CTx FLAURA-2	Dato-DXd +/- <i>Tagrisso</i> TROPION-Lung15/ 01
Other tumour drivers c.12%		<i>Imfinzi</i> / <i>Osi</i> w/ SBRT PACIFIC-4	CRT → <i>Imfinzi</i> PACIFIC	Dato-DXd + <i>Tagrisso</i> TROPION-Lung14	AZD9592 (EGFR/cMET ADC) EGRET
	HER2m c.2%				<i>Enhertu</i> DESTINY-Lung04

 established SoC

Leading the future of lung cancer treatment

- Establishing *Tagrisso* as backbone TKI in EGFRm
- *Imfinzi* leading IO in unresectable
- Advancing best-in-class ADCs to replace systemic chemotherapy
- Delivering next-wave bispecifics to improve on PD1/PD-L1
- Developing novel combinations, including IO + ADCs
- Investing behind new technologies and platforms, including cell therapy and testing/screening



AstraZeneca in Breast Cancer

Ambition to eliminate breast cancer as a cause of death

Established SoC	Early		RECURRENCE	Metastatic				
	Neoadjuvant	Adjuvant		1st line	2nd line	3rd line	4th line +	
Est. epi (G7)	540k			125k	90k	65k	55k	
HER2-positive 15-20%	<i>Enhertu</i> ± THP DESTINY-Breast11	NST → residual disease → <i>Enhertu</i> DESTINY-Breast05		<i>Enhertu</i> ± pertuzumab DESTINY-Breast09	<i>Enhertu</i> DESTINY-Breast03	<i>Enhertu</i> DESTINY-Breast02		
HR-positive 65-75%		Low risk Good outcomes with current SoC		camizestrant + CDK4/6i SERENA-4	<i>Truqap</i> + <i>Faslodex</i> CAPitello291 PIK3CA, AKT1, PTEN alt. 40%	Dato-DXd TROPION-Breast01		
		CTx → camizestrant (± CDK4/6i) CAMBRIA-2		AI + CDK4/6i → camizestrant + CDK4/6i SERENA-6 <i>ESR1m</i> 35%	<i>Enhertu</i> DESTINY-Breast06 HER2-low (1+, 2+) 60% HER2-ultralow (0-1+) 25%		<i>Enhertu</i> DESTINY-Breast04 HER2-low (1+, 2+) 60%	
		CTx → AI (± CDK4/6i) 2-5 yrs → camizestrant CAMBRIA-1		<i>Truqap</i> + <i>Faslodex</i> + CDK4/6i CAPitello292				
TNBC 10-15%	Dato-DXd + <i>Imfinzi</i> TROPION-Breast04	NST → residual disease → Dato-DXd ± <i>Imfinzi</i> TROPION-Breast03		<i>Truqap</i> + paclitaxel CAPitello290	HER2-low (1+, 2+) 35%			
			PD-L1+ 40% Dato-DXd + <i>Imfinzi</i> TROPION-Breast05					
			PD-L1- 60% Dato-DXd TROPION-Breast02					
gBRCAm 5% of HR-positive 15% of TNBC		CTx → <i>Lynparza</i> OlympiA			<i>Lynparza</i> OlympiAD			

All numbers are approximate. Illustrative settings and populations, not to scale.

31 Collaboration partners: Daiichi Sankyo (*Enhertu*, Dato-DXd), Merck & Co., Inc. (*Lynparza*).


Appendix: [Glossary](#).



Oncology


Tagrisso

13% growth at CER to \$3,203m in H1 2024



Lynparza

9% growth at CER to \$1,450m in H1 2024




Due to rounding, the sum of a number of dollar values and percentages may not agree to totals.



Oncology


Imfinzi

25% growth at CER to \$2,259m in H1 2024



Imjudo


38% growth at CER to \$136m in H1 2024



Oncology


Calquence

28% growth at CER to \$1,508m in H1 2024



Enhertu

62% growth at CER to \$932m in H1 2024




Due to rounding, the sum of a number of dollar values and percentages may not agree to totals.



BioPharmaceuticals: Cardiovascular, Renal & Metabolism


Farxiga

38% growth at CER to \$3,836m in H1 2024




Brilinta

2% growth at CER to \$665m in H1 2024



Lokelma


30% growth at CER to \$249m in H1 2024



BioPharmaceuticals: Respiratory & Immunology

Fasenra


6% growth at CER to \$781m in H1 2024



EM	10	12	13	14	14	19	16	22	19
ERoW	36	35	35	35	36	35	36	33	37
Europe	78	77	76	88	89	86	93	93	99
US	230	229	257	201	267	249	275	210	268

Breztri


51% growth at CER to \$454m in H1 2024



EM	21	28	21	38	43	42	38	70	61
ERoW	10	9	9	10	15	12	15	14	19
Europe	9	8	11	15	21	19	26	30	35
US	53	58	75	81	84	98	120	105	120

Tezspire

>2x at CER to \$280m in H1 2024



EM	0	0	0	0	0	0	1	2	3
ERoW	0	0	2	4	8	10	14	14	19
Europe	0	0	2	7	11	11	17	27	35
US	13	26	37	43	62	74	83	77	104


Due to rounding, the sum of a number of dollar values and percentages may not agree to totals.



BioPharmaceuticals: Respiratory & Immunology


Symbicort

19% growth at CER to \$1,491m in H1 2024



Pulmicort


14% growth at CER to \$379m in H1 2024



Rare Disease


Ultomiris

35% growth at CER to \$1,804m in H1 2024




Soliris

8% decrease at CER to \$1,439m in H1 2024



Strensiq

18% growth at CER to \$653m in H1 2024



Due to rounding, the sum of a number of dollar values and percentages may not agree to totals.

